Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
1561 Terbutaline Sulphate 0.5mg/ml Injection R03CC03-183-P30-01-XXX B Bronchial asthma, chronic bronchitis, emphysema and other lung diseases where broncoconstriction is a complicating factor None SC, IM or slow IV : 250-500 mcg up to 4 times daily. CHILD 2 - 15 years 10mcg/kg to a maximum of 300 mcg. Continuous IV infusion, as a solution containing 3 - 5 mcg/ml, 1.5 - 5 mcg/minute for 8 - 10 hours; reduce dose for children
1562 Terbutaline Sulphate 10mg/ml Nebulizer Solution R03AC03-183-A30-01-XXX B Asthma and other conditions associated with reversible airways obstruction None ADULT : 5 - 10 mg 2 -4 times daily, additional doses may be necessary in severe acute asthma. CHILD up to 3 years : 2 mg, 3 - 6 years : 3 mg, 6 - 8 years : 4 mg, over 8 years : 5 mg 2 - 4 times daily
1563 Teriflunomide 14 mg tablet L04AA31-000-T32-01-XXX A* Treatment of adult patients with relapsing remitting multiple sclerosis (MS) 14mg once daily.
1564 Terlipressin 1mg Injection H01BA04000P4001XX A* i. Acute oesophageal variceal bleeding
ii. Treatment of type 1 hepatorenal syndrome, characterised by spontaneous acute renal insufficiency, in patients suffering from severe cirrhosis with ascites.		 None indikasi i:
2 mg IV bolus over 1 minute. Maintenance: 1 - 2 mg IV bolus 4 - 6 hourly until bleeding is controlled, up to 24 - 36 hours. The maximum daily dosage is 120-150 mcg/kg body weight.

indikasi ii:
Terlipressin is usually started at a dose of 1 mg of terlipressin acetate every 4-6 hours. The dose can be increased to a maximum of 12 mg daily, or 2 mg every 4-6 hours, if serum creatinine levels has not decreased by at least 25% after 3 days of treatment.

As an alternative to bolus injection, terlipressin can be administered as a continuous intravenous (IV) infusion with a starting dose of 2 mg of terlipressin acetate/24 hours and increased to a maximum of 12 mg of terlipressin acetate/24 hours.
1565 Testosterone 250 mg/ml Injection G03BA03-000-P30-01-XXX A* i. In male: Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical test.
ii. In female: Additive therapy in cases of advanced breast cancer in postmenopausal women.		 By IM only. Hypogonadism 250 mg every 2-3 weeks. To maintain an adequate androgenic effect 250 mg every 3-6 weeks. Potency disorders 250 mg every 4 weeks. Male climateric disorders: 250 mg every 3-4 weeks. Repeated 6-8 weeks courses at 2-3 months interval
1566 Tetanus Toxoid Vaccine Injection J07AM01-000-P30-01-XXX C+ Immunisation against tetanus infection. None 0.5 mL by IM. Dosing is according to product insert.
1567 Tetracycline HCl 250 mg Capsule J01AA07110C1001XX B Infections caused by susceptible pathogens "Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g daily"
1568 Tetracycline HCl 250 mg Tablet J01AA07110T1001XX B Infections caused by susceptible pathogens "Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g daily"
1569 Thalidomide 50 mg Capsule L04AX02000C1001XX A* Treatment of multiple myeloma. 50 mg to 200 mg daily
1570 Thallous Chloride (Thallium-201) Injection V09GX01100P3001XX A* Used in myocardial perfusion scintigraphy, acute myocardial infarction and post-surgical assessment of coronary artery bypass graft patency, muscle perfusion scintigraphy, visualisation of brain and thyroid tumours and metastases As IV infusion
1571 Theophylline 125mg Tablet R03DA04-000-T10-01-XXX B Reversible airways obstruction, acute severe asthma None ADULT: 125 mg 3 - 4 times daily after food, increased to 250 mg if required.
CHILD: 1 - 15 years : 5 mg/kg/dose (up to 600 mg/ day) every 3 - 4 times daily
1572 Theophylline 250mg Long Acting Tablet R03DA04-000-T50-01-XXX B Reversible airways obstruction and acute severe asthma None ADULT: 250 mg 2 times daily. CHILD under 12 years : Up to 10 mg/kg body weight 2 times daily
1573 Theophylline 80mg/15ml Syrup R03DA04-000-L90-01-XXX B Reversible airways obstruction and acute severe asthma None ADULT : 125 mg 3 - 4 times daily after food, increased to 250 mg if required. CHILD 1 - 15 years : 5 mg/kg/dose (up to 600 mg/day) every 3 - 4 times per day
1574 Thiamine HCl 100mg/ml Injection A11DA01110P3001XX B i) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndrome i) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200- 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose
1575 Thiamine Mononitrate 10mg Tablet A11DA01-221-T10-02-XXX C Prevention and treatment of thiamine deficiency state - Mild chronic deficiency: 5mg to 30mg daily
Severe deficiency: up to 300mg daily
1576 Thiamine Mononitrate 3mg Tablet A11DA01-221-T10-01-XXX C Prevention and treatment of thiamine deficiency state - Mild chronic deficiency: 5mg to 30mg daily
Severe deficiency: up to 300mg daily
1577 Thioguanine 40 mg Tablet L01BB03000T1001XX A For acute leukaemia and chronic granulocytic leukaemia Refer to specific protocols. Usually 100 mg/m2 for 5 - 7 days (acute myeloid leukaemia) or up to 2 weeks (chronic myeloid leukaemia for accelerated/ advanced disease). CHILD: 40 - 60 g/m2 daily according to protocol
1578 Thiopental Sodium 500mg Injection N05CA19-520-P30-01-XXX B i) General anaesthesia, induction
ii) Anticonvulsant for cases resistant to conventional anticonvulsants in the ICU		 None i) ADULT : For induction 200 - 400 mg. For repeat injection 3 - 5 mg/kg over 10 - 15 seconds until desired depth of anaesthesia is obtained. Not FDA approved for use in pediatric patients ii) 75 - 125 mg IV single dose; for local-anaesthetic induced convulsion: 125 - 250 mg IV over 10 minutes
1579 Thymol Compound Gargle A01AD11985M2001XX C For sore throat and minor mouth inflammation To be gargled 3-4 times daily
1580 Thyrotropin alfa 0.9mg/ml Injection H01AB01000P3002XX A* Thyrogen (thyrotropin alfa) is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer. A two-injection regimen is recommended for thyrotropin administration.
The two-injection regimen is thyrotropin 0.9 mg intramuscularly (IM), followed by a second 0.9 mg IM injection 24 hours later.
After reconstitution with 1.2 mL Sterile Water for Injection, 1.0 mL solution (0.9 mg thyrotropin alfa) is administered by intramuscular injection to the buttock.

For radioiodine imaging or treatment, radioiodine administration should be given 24 hours following the final Thyrogen injection. Diagnostic scanning should be performed 48 hours after radioiodine administration, whereas post-therapy scanning may be delayed additional days to allow background activity to decline.
1581 Tibolone 2.5 mg Tablet G03CX01-000-T10-01-XXX A* i. Treatment of complaints resulting from the natural or surgical menopause & in cases at high risk for breast carcinomas where general hormone replacement therapy is contraindicated

ii. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.		 - 2.5mg daily
1582 Ticagrelor 90 mg Tablet B01AC24-000-T10-01-XXX A* Co-administration with aspirin, for the prevention of atherothrombotic events:

a) Second line treatment for patients readmitted to hospital with recurrent atherothrombotic event failing treatment with clopidogrel.
b) STEMI patients going for invasive PCI
c) NSTEMI/UA patients with intermediate to high risk TIMI score
d) Other complicated ACS cases treated either medically or invasively via PCI or CABG (risk of Stent thrombosis, 3VD etc.)		 Initially, 180mg as single dose followed by 90mg bd with maintenance dose of ASA 75-150 mg daily.
1583 Ticlopidine HCl 250 mg Tablet B01AC05110T1001XX A/KK i) Prevention of thrombotic stroke for patients who are sensitive /intolerant to Acetysalicylic Acid ii) Maintenance of coronary bypass surgery or angioplasty iii) Maintenance of patency of access in patients on chronic haemodialysis 250 mg twice daily taken with food
1584 Timolol 0.5% Eye Drops S01ED01-253-D20-02-XX A Elevated intraocular pressure, chronic open angle glaucoma None One drop in the affected eye(s) twice daily or as directed by physician
1585 Timolol 0.5% Ophthalmic Gel Forming Solution S01ED01-253-D20-02-XXX A Elevated intraocular pressure, chronic open angle glaucoma None One drop in the affected eye(s) once a day
1586 Tinidazole 500 mg Tablet P01AB02000T1001XX B i) Amoebiasis ii) Urogenital trichomoniasis and giardiasis i) ADULT : 2 g as a single dose for 2 - 3 days. CHILD 3 years and older : 50 mg/kg daily for 3 days ii) ADULT : 2 g as a single dose (repeated once if necessary). Sexual partners should be treated concomitantly with the same dose. CHILD 6 years and older : single dose of 1 gram
1587 Tiotropium 2.5mcg and Olodaterol 2.5mcg per actuation, inhalation R03AL06-989-A10-01-XXX A/KK As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Patients without inhaler coordination problem (Only applies to Primary Care settings) 2 puffs once daily, at the same time of the day.
1588 Tiotropium 2.5mcg/puff solution for inhalation R03BB04-320-A30-01-XXX A/KK i) Maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
ii) As add-on maintenance bronchodilator treatment in adult patients (18 years and older) with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800µg budesonide/day or equivalent) and long-acting β2-agonist and who experienced one or more severe exacerbations in the previous year.		 For indication (i): The diagnosis of COPD should be confirmed by spirometry.
 5 mcg (2 puff) once daily, at the same time of the day
1589 Tirofiban HCl 0.25 mg/ml Injection B01AC17110P9901XX A* Unstable angina or non-ST segment elevation myocardial infarction with the following: elevated cardiac markers, refractory chest pain, ST-segment changes and thrombolysis in myocardial infarction (TIMI) risk score 4 By IV infusion, 0.4 mcg/kg/min for 30 minutes, then 0.1 mcg/kg/min for at least 48 hours, maximum 108 hours
1590 Tirzepatide 10.0 mg/dose (16.7 mg/mL) Solution for Injection in Pre-filled Pen A10BX16-000-P50-04-xxx A* Weight management: As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of:
i. ≥ 30 kg/m2 (obesity) or
ii. ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).		 i. Adults above 18 years old with T2DM, BMI≥ 32.5 kg/m2 who had:
• Failed lifestyle intervention AND
• Failed one GLP-1 receptor agonist for T2DM

OR

Adults above 18 years old with BMI≥ 37.5 kg/m2 who had:
• Failed lifestyle intervention AND
• With at least one obesity-related comorbidity [obstructive sleep apnoea (OSA), heart failure (HF), chronic kidney disease (CKD) or metabolic dysfunction-associated steatohepatitis (MASH)]

ii. To be prescribed by Endocrinologists only
 Initiate tirzepatide at 2.5 mg weekly for 4 weeks, then increase to 5 mg weekly. If clinically required, escalate in 2.5 mg increments at minimum 4-week intervals to recommended maintenance doses of 5 mg, 10 mg, or a maximum of 15 mg weekly.

Halaman-halaman